Alcon (ALC) Launches Clareon Portfolio in the US

Alcon (NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the Clareon® family of intraocular lenses (IOLs) in the U.S. Utilizing Alcon’s most advanced IOL material, Clareon can deliver consistent visual outcomes and exceptional clarity that lasts.°,1-7 The Clareon clarity is born out of a glistening-free§ IOL material that has among the lowest levels of haze and subsurface nanoglistenings (SSNGs) compared to leading competitor IOLs.†,*,1-3

“We are proud to offer our latest IOL technology in the U.S. and other countries across the globe. At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients,” said Ian Bell, President, Global Business & Innovation, Alcon. “Clareon is the result of robust R&D efforts at every level—inventive material science, advanced manufacturing techniques and novel delivery systems—to deliver exceptional, long-lasting clarity.”

The Clareon portfolio leverages many of the same design characteristics and optics as Alcon’s leading IOLs to help deliver the outcomes surgeons expect.8,9 Clareon offers sharp, crisp vision with a proprietary edge designed to help reduce glare and posterior capsular opacification.7 The lens’ unique and proven STABLEFORCE® Haptics provide superior axial and rotational stability.*,β,8-14 Clareon has been extensively researched, with inclusion in 30 published studies worldwide. Clareon Monofocal and Clareon Toric IOLs have already been implanted in more than one million eyes across more than 70 countries.15

Clareon IOLs are inserted using the next-generation, reusable Clareon Monarch® IV Delivery System, which provides precise and controlled implantation and that was designed specifically for the new Clareon material.15,16 Clareon Monofocal is also available in the next-generation automated, single-use delivery system, AutonoMe™.

“As one of the investigators for the Clareon pivotal trial, I was immediately impressed with the clarity of the new IOL material, delivery system and the consistent refractive outcomes,” said Dr. Samuel H. Lee, MD, Ophthalmologist, Sacramento, CA.** “Today, the clarity of Clareon persists four years later in my trial patients, with the optic performance that I expect from Alcon IOLs, as well as continued high patient satisfaction.”

Clareon Monofocal, Clareon PanOptix®, Clareon PanOptix Toric, Clareon Vivity® and Clareon Vivity Toric IOLs are now available in the U.S. Clareon PanOptix offers patients the possibility of 20/20 vision at distance (far), intermediate (at arm’s length) and near (up close), with continuous vision of 20/25 or better.¥,14,17 Clareon Vivity is a non-diffractive extended depth of focus lens with wavefront-shaping X-WAVE™ technology, delivering monofocal-quality distance with excellent intermediate and functional near vision and with a monofocal visual disturbance profile.13,18

Clareon Toric will be available in the U.S. later this year. Alcon will be rolling out the Clareon family of IOLs in international markets throughout 2022 and 2023.

There are more than 28 million cataract surgeries performed each year in the world. With the aging population and increased life expectancies, these surgeries are expected to increase 3-4% per year for the next 30 years, leading to an estimated 60 million global cataract surgeries annually by 2045.19

You May Also Be Interested In

• eToro Group (ETOR) Files for Proposed IPO
• Oklo Inc (OKLO) Publishes Full Year 2024 Financial Results and Business Update
• Faraday Future Intelligent Electric (FFAI) Secures New $41 Million Funding Commitment to Advance Faraday X (FX) and AI Strategic Upgrades